# A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension

> **NCT05932459** · PHASE1 · COMPLETED · sponsor: **Vigonvita Life Sciences** · enrollment: 38 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Deuremidevir Hydrobromide for Suspension 100mg
- **DRUG:** Deuremidevir Hydrobromide for Suspension 300mg
- **DRUG:** Deuremidevir Hydrobromide for Suspension 25mg
- **DRUG:** Deuremidevir Hydrobromide tablets 100mg

## Key facts

- **NCT ID:** NCT05932459
- **Lead sponsor:** Vigonvita Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-09
- **Primary completion:** 2023-09-04
- **Final completion:** 2023-09-04
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05932459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05932459, "A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05932459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*